On the contrary, silencing of LRP5 suppressed the tumorigenicity and sensitized CRC to cisplatin treatment by targeting Wnt/β‐catenin mediated CSC properties and IL‐6/STAT3 pathway. This evidence concerns the gene IL6 and colorectal carcinoma.